5 results about "Interferon receptor" patented technology

This invention provides an application of type I interferon signaling pathway inhibitors in the preparation of drugs for treating age-related cataracts. By inhibiting type I interferon receptors, it can precisely intervene in the aging mechanism of lens epithelial cells, block the transmission of aging signals, and directly improve lens transparency, exhibiting higher therapeutic efficacy and targeting. The use of IFNAR inhibitors can effectively reverse the aging phenotype caused by STEAP3 deficiency, restore the proliferative capacity of lens epithelial cells, thereby maintaining lens transparency, significantly reducing surgical risks, and providing patients with an early intervention opportunity, delaying the onset and progression of cataracts. IFNAR inhibitors, through precise intervention in specific signaling pathways, have more significant therapeutic effects, and due to their targeting, have fewer side effects and are safer. They can not only improve existing cataracts but also play a preventive and delaying role in the early stages of cataracts. For patients with mild cataracts, the use of type I interferon receptor inhibitors can avoid premature surgical treatment, reducing patient dependence on surgery and also reducing the costs and risks associated with surgery.

This disclosure provides immune cells (e.g., CAR-T cells) comprising a chimeric antigen receptor and / or an engineered immune cell receptor, that are deficient in interferon y receptor (IFNyR) expression and / or signaling, and methods of use thereof, wherein the CAR-immune cell have increased persistence.

This invention provides a method and unit dose for the treatment of type I IFN-mediated diseases. [Solution] The present invention provides a unit dose for subcutaneous administration of a type I IFN receptor (IFNAR1) inhibitor in a dose greater than 105 mg (>) and less than 150 mg (<), specifically a human monoclonal antibody specific to IFNAR1, or optionally a modified IgG1 class human monoclonal antibody, and a method comprising subcutaneously administering the unit dose to a subject having a type I interferon (IFN)-mediated disease.

An interferon α2b mutant, and a fusion polypeptide and polypeptide construct comprising same. The fusion polypeptide or polypeptide construct comprising the interferon α2b mutant has weakened affinity to an interferon receptor, reduced off-target toxicity, and a tumor killing effect.

This disclosure relates to methods and compositions for the treatment of SLE. Specifically, this disclosure relates to methods including the administration of type I IFN receptor inhibitors.